Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit – Hagens Berman

Group 1 - A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, allowing new investors to apply by September 24, 2025 [1][2] - The class period for the lawsuit is from March 17, 2022, to September 22, 2022, and the case has survived a motion to dismiss [3][4] - The lawsuit alleges that Spectrum misled investors about the success of its cancer treatment drug, poziotinib, leading to a share price drop of over 37% when FDA concerns were revealed [3][4] Group 2 - Assertio Holdings (ASRT) acquired Spectrum Pharmaceuticals in July 2023, allowing investors who received ASRT shares after acquiring SPPI shares during the class period to potentially represent the class [5] - Hagens Berman is encouraging investors who suffered significant losses to consider becoming the new lead plaintiff, emphasizing the importance of this role in overseeing litigation [6]